Selegiline orally disintegrating tablets for the treatment of Parkinson’s disease

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Expert Review of Neurotherapeutics

• Publication date

  2005-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1586/14737175.5.6.705PMID 16274328
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Parkinson's disease].

  2022cited by this paper
• Impact of the motor complications of Parkinson's disease on the quality of life

  2005cited by this paper
• Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial.

  2005cited by this paper
• Management of motor complications in Parkinson’s disease

  2004cited by this paper
• Neuronal pathology in Parkinson’s disease

  2004cited by this paper
• Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study

  2004cited by this paper
• Parkinson's disease

  2004cited by this paper
• Prepharyngeal dysphagia in Parkinson's disease

  2004cited by this paper
• Levodopa in the treatment of Parkinson's disease: Current controversies

  2004cited by this paper
• Clinical experience with the novel levodopa formulation entacapone + levodopa + carbidopa (Stalevo®)

  2004cited by this paper
• A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

  2003cited by this paper
• A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition

  2003cited by this paper
• Physiology and Pathophysiology of Parkinson's Disease

  2003cited by this paper
• Current concepts in the diagnosis and management of Parkinson's disease.

  2003cited by this paper
• Levodopa strengths and weaknesses

  2002cited by this paper
• Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy

  2002cited by this paper
• [Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].

  2001cited by this paper
• Parkinson's disease. Update in diagnosis and symptom management.

  2001cited by this paper
• Evolution of motor fluctuations in Parkinson's disease: A longitudinal study over 6 years

  1999cited by this paper
• Safety of Selegiline (Deprenyl) in the Treatment of Parkinson’s Disease

  1998cited by this paper
• Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease.

  1998cited by this paper
• Parkinson's disease. Second of two parts.

  1998cited by this paper
• Drug‐delivery Products and the Zydis Fast‐dissolving Dosage Form *

  1998cited by this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Selegiline

  1997cited by this paper
• Metabolism of selegiline in humans. Identification, excretion, and stereochemistry of urine metabolites.

  1997cited by this paper
• Swallowing difficulty in Parkinson's disease.

  1997cited by this paper
• Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson’s disease

  1997cited by this paper
• Prepharyngeal dysphagia in Parkinson's disease

  1996cited by this paper
• Drenching sweats as an off phenomenon in parkinson's disease: Treatment and relation to plasma levodopa profile

  1995cited by this paper
• Severe adverse interaction between pethidine and selegiline.

  1991cited by this paper
• L‐Deprenyl (Selegiline) Added to Sinemet CR in the Management of Parkinson's Disease Patients With Motor Response Fluctuations

  1991cited by this paper
• Long‐term efficacy and safety of deprenyl (selegiline) in advanced Parkinson's disease

  1989cited by this paper
• R 56865 differentiates between contractile agents with respect to the nifedipine-sensitive component in the isolated rat aorta.

  1989cited by this paper
• Motor complications associated with chronic levodopa therapy in Parkinson's disease.

  1989cited by this paper
• Dietary tyramine and other pressor amines in MAOI regimens: a review.

  1986cited by this paper
• Dietary tyramine and other pressor amines in MAOI regimens: a review.

  1986cited by this paper
• On-off fluctuations in Parkinson's disease. A clinical and neuropharmacological study.

  1984cited by this paper

• Discontinuation or acute unplanned cessation of oral dopaminergic medications in persons with Parkinson's disease: A practice review

  2025cites this paper
• Development, characterization and pharmacokinetic evaluation of selegiline HCl loaded cubosomal thermoreversible mucoadhesive gel for nose to brain delivery

  2024cites this paper
• Development of Lyophilisates Based on Polymer-drug and Interpolyelectrolyte Complexes: Pharmacokinetic Assessment

  2023cites this paper
• Halide counterions in FDA-approved pharmaceutical salts

  2023cites this paper
• Safety review of current pharmacotherapies for levodopa-treated patients with Parkinson’s disease

  2023cites this paper
• Comparative Evaluation of Metformin and Metronidazole Release from Oral Lyophilisates with Different Methods

  2023cites this paper
• Oral Health and Use of Novel Transbuccal Drug Delivery Systems in Patients with Alzheimer’s and Parkinson’s Disease: A Review

  2023cites this paper
• Formulation and Development of Candesartan Cilexetil Fast Dissolving Tablets by Sublimation Technique

  2019cites this paper
• Overview on the Orally Disintegrating Tablet Formulations

  2019cites this paper
• Brain targeted delivery of mucoadhesive thermosensitive nasal gel of selegiline hydrochloride for treatment of Parkinson's disease

  2018cites this paper
• Pharmacological Strategies for the Management of Levodopa-Induced Dyskinesia in Patients with Parkinson’s Disease

  2014cites this paper
• Investigation, development and evaluation of orally disintegrating tablets

  2014cites this paper
• Oral Disintegrating Tablets A Current Review

  2013cites this paper
• Design and Development of Fast Dissolving Tablets of Felodipine Using Different Methods

  2012cites this paper
• Advantages and Quality Control of Orally Disintegrating Tablets

  2012cites this paper
• FORMULATION AND EVALUATION OF FAST DISSOLVING TABLETS OFCANDESARTAN CILEXETIL USING NATURAL AND SYNTHETICSUPERDISINTEGRANTS

  2011cites this paper
• Ağızda Dağılan Tabletler II: In Vitro ve In Vivo Değerlendirilmeleri

  2011cites this paper
• Medical treatment of Parkinson disease.

  2009cites this paper
• Treatment challenges in Parkinson's disease.

  2008cites this paper
• The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy

  2008influential citation
• The increasing role of monoamine oxidase type B inhibitors in Parkinson's disease therapy.

  2008cites this paper
• Neuroreplacement, growth factor, and small molecule neurotrophic approaches for treating Parkinson's disease.

  2007cites this paper
• Optimizing bioavailability in the treatment of Parkinson's disease.

  2007cites this paper
• Medical Management of Levodopa-Associated Motor Complications in Patients with Parkinson’s Disease

  2007cites this paper
• Laser Literature Watch

  2006cites this paper
• Novel transdermal delivery formulation of the monoamine oxidase inhibitor selegiline nearing release for treatment of depression.

  2006cites this paper
• Laser literature watch.

  2006cites this paper
• Deprenyl: from chemical synthesis to neuroprotection.

  2006cites this paper